FBXW4 and acute myeloid leukemia: Our results indicated that FBXW4 is aberrantly expressed in AML patients, and its high expression is associated with high risk factors and poor prognosis; particularly, it is an independent poor survival factor in patients with intensive chemotherapy and allo-SCT therapy.